File
Authors
Wakahara, Makoto Division of General Thoracic Surgery and Breast and Endocrine Surgery, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University Researchers DB
Hosoya, Keiko Division of General Thoracic Surgery and Breast and Endocrine Surgery, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University / Department of Pathology, School of Medicine, Faculty of Medicine, Tottori University
Ishii, Hiroshi Department of Pathology, School of Medicine, Faculty of Medicine, Tottori University
Umekita, Yoshihisa Department of Pathology, School of Medicine, Faculty of Medicine, Tottori University Researchers DB KAKEN
Keywords
breast carcinoma
immunohistochemistry
maspin
Abstract
Background: Maspin is known to be a tumor suppressor protein: however, its prognostic value in patients with breast cancer remains controversial. The key influential factors contributing to this complexity may be the differences in antibodies used, as well as the positive criteria and sample size. To date, no study has investigated the prognostic significance of maspin expression by using two different antibodies in the same cohort. We aimed to clarify whether differences in antibodies could influence on the prognostic value of maspin in breast cancer patients. Methods: Immunohistochemical analyses using an anti-maspin antibody (clone G167-70) were performed on 164 resected specimens of invasive carcinoma of no special type (NOS). The correlation with clinicopathological factors was compared to previous results using clone EAW24, with longer follow-up duration. Results: The subcellular localization of maspin expression was as follows: cytoplasmic-only staining, 3 cases (1.8%), pancellular staining, 43 cases (26.2%); and no staining, 118 cases (72.0%). No nuclear-only staining was observed. There was no significant correlation between clinicopathological characteristics and the pancellualr expression of maspin. The pancellular expression group showed a significantly longer disease-free survival (DFS) than the other groups (P = 0.046). When clone EAW24 was used, the cytoplasmic-only staining group showed significantly shorter DFS than the pancellular staining group (P = 0.003). Conclusion: Clone EAW24 may be superior to clone G167-70 in selecting breast carcinoma with an aggressive phenotype, while clone G167-70 may be superior to clone EAW24 in selecting non-aggressive breast carcinoma.
Publisher
Tottori University Medical Press
Content Type
Journal Article
Link
ISSN
05135710
EISSN
13468049
NCID
AA00892882
Journal Title
Yonago Acta Medica
Current Journal Title
Yonago Acta Medica
Volume
66
Issue
1
Start Page
19
End Page
23
Published Date
2023-02-20
Publisher-DOI
Text Version
Publisher
Rights
(C) 2023 Tottori University Medical Press.
Citation
Yonago Acta Medica. 2023, 66(1), 19-23. doi10.33160/yam.2023.02.003
Department
Faculty of Medicine/Graduate School of Medical Sciences/University Hospital
Language
English